comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 18:17:08 - browse：92661

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

focus

WSS

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Take antibiotics after sex, CDC recommends for certain risk groups

UnitedHealth CEO's Medicaid comments send insurer stocks diving

BMS, looking to build heart drug business, turns to AI for diagnosis

FTC loses bid to block Novant's North Carolina hospital merger

Be careful with at

Wikipedia

comprehensive

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Be careful with at

State Dept. review finds Biden bears some blame for Afghanistan failures

Mark Cuban is blaming the wrong people for high drug costs

Trump demands the U.S. pay no more for drugs than other countries … again

Novo Nordisk touts Wegovy study, but still struggling with supply

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Eli Lilly’s Zepbound improved liver scarring in mid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Take antibiotics after sex, CDC recommends for certain risk groups

focus

Eli Lilly’s Zepbound improved liver scarring in mid

Biogen’s boardroom scandal saddles CEO with first crisis

Novo Nordisk touts Wegovy study, but still struggling with supply

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Eli Lilly’s Zepbound improved liver scarring in mid

How CO2 helps viruses stay alive longer in the air

focus

focus

leisure time

leisure time